Bozko Maria, Bozko Andrzej, Scholta Tim, Malek Nisar P, Bozko Przemyslaw
Faculty of Biology, University of Warsaw, Warsaw, Poland.
Department of Internal Medicine I, Eberhard Karls University Tubingen Tubingen. Germany.
Curr Med Chem. 2017;24(15):1487. doi: 10.2174/092986732415170630115722.
Amongst all currently used drugs in the field of cancer therapy, the most prominent group of agents which induce DNA, damage both directly or indirectly. Intuitively DNA should not be a perfect target for relatively unspecific small molecular weight drugs. However, the current understanding is that not damage per se but cellular response to DNA damage induced by antitumor agents is responsible for their specific targeted effect towards cancer cells in comparison to the normal cells. DNA damaging chemotherapeutics include compounds with diferent activities namely: directly or indirectly induce DNA strand breaks, covalently modify DNA bases, change the chromatin structure and topology by inhibiting chromatin-modifying enzymes. In this special issue of Current Medicinal Chemistry entitled....
在癌症治疗领域目前使用的所有药物中,最突出的一类药物是直接或间接诱导DNA损伤的药物。直观地说,DNA对于相对非特异性的小分子药物而言不应是一个完美的靶点。然而,目前的认识是,与正常细胞相比,抗肿瘤药物诱导的DNA损伤本身并非其对癌细胞具有特异性靶向作用的原因,而是细胞对DNA损伤的反应起了作用。DNA损伤性化疗药物包括具有不同活性的化合物,即:直接或间接诱导DNA链断裂、共价修饰DNA碱基、通过抑制染色质修饰酶改变染色质结构和拓扑结构。在本期名为《当代药物化学》的特刊中……